GLOW 70 mg — Regeneration & Repair Research Blend
Formulation: GHK-Cu 50 mg • BPC-157 10 mg • TB-500 10 mg
GLOW combines three research peptides studied for complementary roles in tissue remodeling, cellular repair, wound-healing pathways, angiogenesis, collagen regulation, and inflammatory signaling. GHK-Cu is particularly investigated for collagen synthesis and skin/tissue remodeling, while BPC-157 and TB-500 are studied experimentally for mechanisms associated with tissue recovery, vascular responses, and cellular migration.
Together, the 70 mg blend provides researchers with a formulation for investigating regenerative signaling and tissue-repair pathways.
For laboratory and research use only. Not for human consumption.
GLOW 70 mg — Regeneration & Repair Research Blend
Formulation: GHK-Cu 50 mg • BPC-157 10 mg • TB-500 10 mg
GLOW combines three research peptides studied for complementary roles in tissue remodeling, cellular repair, wound-healing pathways, angiogenesis, collagen regulation, and inflammatory signaling. GHK-Cu is particularly investigated for collagen synthesis and skin/tissue remodeling, while BPC-157 and TB-500 are studied experimentally for mechanisms associated with tissue recovery, vascular responses, and cellular migration.
Together, the 70 mg blend provides researchers with a formulation for investigating regenerative signaling and tissue-repair pathways.
For laboratory and research use only. Not for human consumption.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
on orders over $200
plain and unbranded packaging
256-bit SSL
Not a researcher? Exit
